Treat Cancer at Any Stage
A New Weapon in the War on Cancer: Kill Tumors and Activate a Systemic Immune Response
Treat locally, act globally. Intensity’s novel intratumoral delivery technology creates drug products that kill cancer cells in a manner that enables immune cells to enter and attack tumors throughout the body. Our vision is to meaningfully extend the lives of patients with metastatic cancer while maintaining their quality of life; for presurgical patients our mission is to avoid disease recurrence.

A New Weapon in the War on Cancer: Kill Tumors and Activate a Systemic Immune Response
Treat locally, act globally. Intensity’s novel intratumoral delivery technology creates drug products that kill cancer cells in a manner that enables immune cells to enter and attack tumors throughout the body. Our vision is to meaningfully extend the lives of patients with metastatic cancer while maintaining their quality of life; for presurgical patients our mission is to avoid disease recurrence.


Tumor
Injection
DfuseRx℠ is our novel proprietary penetration enhancer platform technology that enables therapeutic agents to be injected directly into solid tumors for improved absorption.

Diffusion
Through Tumor
Once injected, DfuseRx enables the injected drug solution to disperse throughout the tumor and increases the drug’s diffusion into cancer cells.

Localized
Cell Death
The absorbed active agents in the injected tumor induce cancer cell death, without disruption of the cell membrane, in a manner that results in an influx of immune cells throughout the tumor.

System-wide
Immune Response
Tumor cell death exposes the immune system to antigens of the patient’s own cancer, inducing a personalized CD4+ and CD8+ T cell response, attacking the site of the former tumor while attacking distal cancer sites.
Increased
Survival
Exploratory analysis of data from a Phase 1/2 trial of relapsed and refractory solid tumor patients with a variety of cancers indicates an association between percent of tumor burden treated and survival.
Technology and Clinical Data

Latest News
-
Intensity Therapeutics' Reports Up to 100% Tumor Necrosis After One Dose of Lead Asset, INT230-6 in Phase 2 INVINCIBLE Neoadjuvant Breast Cancer Study at the San Antonio Breast Cancer Symposium (SABCS)
Dec 08, 2022
-
Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2022
Nov 18, 2022
-
Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers
Nov 11, 2022
Register for News Updates:
Subscribe to our company news email list and receive news as it is released. Your privacy is important, and your email address will be used only for this news distribution list.
Latest Tweets:
All #ASCO posters and presentations can be seen on the publications page on our website. http://www.intensitytherapeutics.com
At #ASCO22 three @IntensityInc abstacts were selected for 3 poster and 2 podium discussion session. Data in #sarcoma and #breastcancer for INT230-6 alone, and in other #Cancers combined with Keytruda and INT230-6 with Yervoy were shown.
At the same time INT230-6 data alone and combined with Keytruda was just discussed and presented at #ASCO22 in live podium discussion session. Dr. Jacob Thomas from USC was on the podium to answer questions.
Our drug INT23-6 data was just discussed and presented at #ASCO22 in live podium discussion session. Dr. Matthew Ingham from Columbia Presbyterian was on the podium to answer questions from the audience.
Please read today's news release at https://bit.ly/3tdZ4wl about our excellent data in #sarcoma reporting increased survival and favorable safety for our drug INT230-6